Pembrolizumab and Olaparib Combination Therapy Shows Antitumor Activity and Acceptable Safety for Pretreated mCRPC
The nonrandomized, multicenter, multicohort, open-label, phase 1b/2 KEYNOTE-365 trial evaluated the safety, tolerability, and efficacy of pembrolizumab combination therapy in men with mCRPC.